Insmed (INSM) Receivables (2010 - 2026)

Insmed's Receivables history runs 11 years deep, the most recent figure standing at $178.6 million for Q1 2026.

• On a quarterly basis, Receivables rose 273.97% year-over-year to $178.6 million in Q1 2026; TTM through Mar 2026 was $178.6 million, a 273.97% increase from a year earlier, with the FY2025 full-year figure at $140.9 million, up 170.82% from the prior year.
• Receivables advanced to $178.6 million in Q1 2026 per INSM's latest filing, from $140.9 million in the prior quarter.
• Across five years, Receivables topped out at $178.6 million in Q1 2026 and bottomed at $25.7 million in Q1 2022.
• The 5-year median for Receivables is $40.3 million (2024), against an average of $53.5 million.
• Across the five-year window, Receivables gained 4.97% in 2023 and soared 273.97% in 2026, its largest moves.
• Year by year, Receivables stood at $29.7 million in 2022, then soared by 38.62% to $41.2 million in 2023, then climbed by 26.28% to $52.0 million in 2024, then soared by 170.82% to $140.9 million in 2025, then climbed by 26.76% to $178.6 million in 2026.
• Per Business Quant, the three latest INSM Receivables figures stand at $178.6 million (Q1 2026), $140.9 million (Q4 2025), and $65.3 million (Q3 2025).